Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24110371 | 0.96 | HTR2C (0.50) | HTR2CPRMT5MTNR1AMTNR1BHTR7 | |
| SCHEMBL24110424 | 0.87 | HTR2C (0.47) | HTR2CPRMT5MTNR1AMTNR1BHTR7 | |
| SCHEMBL25817734 | 0.82 | HTR2C (0.44) | HTR2CPRMT5MTNR1AMTNR1BKDM4E | |
| SCHEMBL18997057 | 0.80 | HTR2C (0.59) | HTR2CPRMT5MTNR1AMTNR1BKDM4E | |
| SCHEMBL24110432 | 0.79 | HTR2C (0.46) | HTR2CPRMT5MTNR1AMTNR1BHTR7 | |
| SCHEMBL24110213 | 0.77 | HTR2C (0.60) | HTR2CPRMT5MTNR1AMTNR1BKDM4E | |
| SCHEMBL23927836 | 0.77 | HTR7 (0.67) | HTR2CPRMT5MTNR1AMTNR1BHTR7 | |
| SCHEMBL23927918 | 0.75 | HTR7 (0.68) | HTR2CPRMT5MTNR1AMTNR1BHTR7 | |
| SCHEMBL24109924 | 0.75 | HTR2C (0.54) | HTR2CPRMT5MTNR1AMTNR1BKDM4E | |
| SCHEMBL29904400 | 0.75 | HTR2C (0.54) | HTR2CPRMT5MTNR1AMTNR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | HTR2C 35/4885PRMT5 1869/4885MTNR1A 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.